Keywords: sanofi, avapro, fails, pass, panel, review, despite
Sanofi's Avapro fails to pass panel review
Article | 28 January 2002
Despite a positive verdict on the application by the US Food and DrugAdministration, Sanofi-Synthelabo and Bristol-Myers Squibb's angiotensin II receptor ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- InSite Vision joins Merck & Co and Pfizer in patent infringement law suit against
- Osteoporosis drug bazedoxifene stops growth of breast cancer cells, even in resistant tumors
- Highlights of EHA meeting: Novartis' Jakavi; Bristol-Myers and AbbVie's elotuzumab; Janssen's ibrutinib
- Additional indications in Japan for Roche's Avastin and Astellas' Prograf
- US Supreme Court says patent settlement can "sometimes" be illegal
